Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2011 2
2012 2
2014 1
2015 3
2016 2
2018 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
Pérez-Ruixo C, Valenzuela B, Fernández Teruel C, González-Sales M, Miguel-Lillo B, Soto-Matos A, Pérez-Ruixo JJ. Pérez-Ruixo C, et al. Among authors: miguel lillo b. Cancer Chemother Pharmacol. 2012 Jan;69(1):15-24. doi: 10.1007/s00280-011-1644-6. Epub 2011 May 18. Cancer Chemother Pharmacol. 2012. PMID: 21590449 Clinical Trial.
Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial).
Petty R, Anthoney A, Metges JP, Alsina M, Gonçalves A, Brown J, Montagut C, Gunzer K, Laus G, Iglesias Dios JL, Miguel-Lillo B, Bohan P, Salazar R. Petty R, et al. Among authors: miguel lillo b. Cancer Chemother Pharmacol. 2016 Apr;77(4):819-27. doi: 10.1007/s00280-016-2991-0. Epub 2016 Mar 10. Cancer Chemother Pharmacol. 2016. PMID: 26964995 Clinical Trial.
Plitidepsin has a safe cardiac profile: a comprehensive analysis.
Soto-Matos A, Szyldergemajn S, Extremera S, Miguel-Lillo B, Alfaro V, Coronado C, Lardelli P, Roy E, Corrado CS, Kahatt C. Soto-Matos A, et al. Among authors: miguel lillo b. Mar Drugs. 2011;9(6):1007-1023. doi: 10.3390/md9061007. Epub 2011 Jun 9. Mar Drugs. 2011. PMID: 21747745 Free PMC article. Clinical Trial.
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
Candelaria M, Gonzalez D, Fernández Gómez FJ, Paravisini A, Del Campo García A, Pérez L, Miguel-Lillo B, Millán S. Candelaria M, et al. Among authors: miguel lillo b. Cancer Chemother Pharmacol. 2018 Mar;81(3):515-527. doi: 10.1007/s00280-018-3524-9. Epub 2018 Jan 24. Cancer Chemother Pharmacol. 2018. PMID: 29362903 Clinical Trial.
Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.
Goel S, Viteri S, Morán T, Coronado C, Dios JL, Miguel-Lillo B, Fernández-García EM, Rosell R. Goel S, et al. Among authors: miguel lillo b. Invest New Drugs. 2016 Feb;34(1):75-83. doi: 10.1007/s10637-015-0305-8. Epub 2015 Dec 2. Invest New Drugs. 2016. PMID: 26627080 Clinical Trial.
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
Ratain MJ, Geary D, Undevia SD, Coronado C, Alfaro V, Iglesias JL, Schilsky RL, Miguel-Lillo B. Ratain MJ, et al. Among authors: miguel lillo b. Invest New Drugs. 2015 Aug;33(4):901-10. doi: 10.1007/s10637-015-0247-1. Epub 2015 May 8. Invest New Drugs. 2015. PMID: 25947566 Clinical Trial.